A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics.

Following positive top-line data released in May, Akili Interactive announced it will release its video game treatment for attention deficit hyperactivity disorder to adults who want to use it.

Attention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were ...

Akili Interactive has revealed the findings of a trial of its digital therapeutic (DTx) for attention-deficit hyperactivity disorder (ADHD) in adults, suggesting it may be more effective in this ...

Akili’s marquee product is EndeavorRx, which they describe as a "first-of-its-kind attention treatment for children with ADHD, delivered through an action video game experience.” EndeavorRx is ...

Clinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD “This FDA ...

Though it’s currently cleared by the FDA to lessen attention-deficit/hyperactivity disorder (ADHD) symptoms only in children between the ages of 8 and 12, Akili ...

Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer Dr. Kollins brings decades of experience driving novel approaches to psychopharmacology and ADHD treatment Download ...

People ages 18 and up with ADHD can now access a version of the therapy over the counter, without requiring a prescription, Akili announced Wednesday. Though the company is still planning on ...

Digital health company Akili Interactive has agreed a deal that could see its gamified therapy for attention-deficit hyperactivity disorder (ADHD) hosted on the creative gaming platform Roblox ...

Akili Inc AKLI announced the topline results of the STARS-ADHD-Adult trial evaluating EndeavorRx (AKL-T01) in adults with attention deficit/hyperactivity disorder (ADHD). The trial ...

BOSTON--(BUSINESS WIRE)-- Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts ...